Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Melanoma 2Carcinoma 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 12Cisplatin 11Hyperthermic Intraperitoneal Chemotherapy 10Cytoreduction Surgical Procedures 9Oxaliplatin 8Fluorouracil 7Mitomycin 6Carboplatin 5Leucovorin 4Bevacizumab 4catumaxomab 3Doxorubicin 3Docetaxel 3sodium thiosulfate 2Indocyanine Green 2Drug Therapy 2Cetuximab 2volociximab 1vandetanib 1relacorilant 1pasireotide 1nilotinib 1farletuzumab 1epothilone B 1enzastaurin 1birinapant 1alvimopan 1Surgical Procedures, Operative 1Saline Waters 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peritoneal Neoplasms × volociximab × Clear all
NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡